Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation

被引:7
作者
Samaras, Athanasios [1 ]
Vrana, Eleni [1 ]
Kartas, Anastasios [1 ]
Moysidis, Dimitrios, V [1 ]
Papazoglou, Andreas S. [1 ]
Doundoulakis, Ioannis [1 ]
Fotos, George [1 ]
Rampidis, Georgios [1 ]
Tsalikakis, Dimitrios G. [2 ]
Efthimiadis, Georgios [1 ]
Karvounis, Haralambos [1 ]
Tzikas, Apostolos [1 ,3 ]
Giannakoulas, George [1 ]
机构
[1] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Dept Cardiol 1, St Kiriakidi 1, Thessaloniki 54636, Greece
[2] Univ Western Macedonia, Dept Informat & Telecommun Engn, Kozani, Greece
[3] Interbalkan European Med Ctr, Thessaloniki, Greece
关键词
Valvular heart disease; Stenosis; Regurgitation; Atrial fibrillation; Prognosis; Outcomes; THROMBOEMBOLIC EVENTS; ANTICOAGULATED PATIENTS; MITRAL REGURGITATION; EUROPEAN ASSOCIATION; ORAL ANTICOAGULANTS; VALVE DISEASE; WARFARIN; AF; EPIDEMIOLOGY; OUTCOMES;
D O I
10.1186/s12872-021-02264-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Valvular heart disease (VHD) in non-valvular atrial fibrillation (AF) is a puzzling clinical entity. The aim of this study was to evaluate the prognostic effect of significant VHD (sVHD) among patients with non-valvular AF. Methods This is a post-hoc analysis of the MISOAC-AF trial (NCT02941978). Consecutive inpatients with non-valvular AF who underwent echocardiography were included. sVHD was defined as the presence of at least moderate aortic stenosis (AS) or aortic/mitral/tricuspid regurgitation (AR/MR/TR). Cox regression analyses with covariate adjustments were used for outcome prediction. Results In total, 983 patients with non-valvular AF (median age 76 [14] years) were analyzed over a median follow-up period of 32 [20] months. sVHD was diagnosed in 575 (58.5%) AF patients. sVHD was associated with all-cause mortality (21.6%/yr vs. 6.5%/yr; adjusted HR [aHR] 1.55, 95% confidence interval [CI] 1.17-2.06; p = 0.02), cardiovascular mortality (16%/yr vs. 4%/yr; aHR 1.70, 95% CI 1.09-2.66; p = 0.02) and heart failure-hospitalization (5.8%/yr vs. 1.8%/yr; aHR 2.53, 95% CI 1.35-4.63; p = 0.02). The prognostic effect of sVHD was particularly evident in patients aged < 80 years and in those without history of heart failure (p for interaction < 0.05, in both subgroups). After multivariable adjustment, moderate/severe AS and TR were associated with mortality, while AS and MR with heart failure-hospitalization. Conclusion Among patients with non-valvular AF, sVHD was highly prevalent and beared high prognostic value across a wide spectrum of clinical outcomes, especially in patients aged < 80 years or in the absence of heart failure. Predominantly AS, as well as MR and TR, were associated with worse prognosis.
引用
收藏
页数:12
相关论文
共 34 条
[1]   Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial [J].
Avezum, Alvaro ;
Lopes, Renato D. ;
Schulte, Phillip J. ;
Lanas, Fernando ;
Gersh, Bernard J. ;
Hanna, Michael ;
Pais, Prem ;
Erol, Cetin ;
Diaz, Rafael ;
Cecilia Bahit, M. ;
Bartunek, Jozef ;
De Caterina, Raffaele ;
Goto, Shinya ;
Ruzyllo, Witold ;
Zhu, Jun ;
Granger, Christopher B. ;
Alexander, John H. .
CIRCULATION, 2015, 132 (08) :624-632
[2]   Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis [J].
Banerjee, Amitava ;
Allan, Victoria ;
Denaxas, Spiros ;
Shah, Anoop ;
Kotecha, Dipak ;
Lambiase, Pier D. ;
Jacob, Joseph ;
Lund, Lars H. ;
Hemingway, Harry .
EUROPACE, 2019, 21 (12) :1776-1784
[3]  
Baumgartner H, 2018, EUR HEART J, V39, P1980, DOI [10.1093/eurheartj/ehx636, 10.1093/eurheartj/ehx391]
[4]  
Bax JJ., 2020, EUR HEART J, DOI [10.1093/eurheartj/ehaa612/5899003, DOI 10.1093/EURHEARTJ/EHAA612/5899003]
[5]   Stroke and Thromboembolism in Patients With Atrial Fibrillation and Mitral Regurgitation [J].
Bisson, Arnaud ;
Bernard, Anne ;
Bodin, Alexandre ;
Clementy, Nicolas ;
Babuty, Dominique ;
Lip, Gregory Y. H. ;
Fauchier, Laurent .
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2019, 12 (03)
[6]   MITRAL REGURGITATION ASSOCIATED WITH REDUCED THROMBOEMBOLIC EVENTS IN HIGH-RISK PATIENTS WITH NONRHEUMATIC ATRIAL-FIBRILLATION [J].
BLACKSHEAR, JL ;
PEARCE, LA ;
ASINGER, RW ;
DITTRICH, HC ;
GOLDMAN, ME ;
ZABALGOITIA, M ;
ROTHBART, RM ;
HALPERIN, JL .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 72 (11) :840-843
[7]   Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban [J].
Breithardt, Guenter ;
Baumgartner, Helmut ;
Berkowitz, Scott D. ;
Hellkamp, Anne S. ;
Piccini, Jonathan P. ;
Lokhnygina, Yuliya ;
Halperin, Jonathan L. ;
Singer, Daniel E. ;
Hankey, Graeme J. ;
Hacke, Werner ;
Becker, Richard C. ;
Nessel, Christopher C. ;
Mahaffey, Kenneth W. ;
Califf, Robert M. ;
Fox, Keith A. A. ;
Patel, Manesh R. .
HEART, 2016, 102 (13) :1036-1043
[8]   Valvular heart disease among non-valvular atrial fibrillation: amisnomer, in search of a new term [J].
Breithardt, Guenter ;
Baumgartner, Helmut .
EUROPEAN HEART JOURNAL, 2015, 36 (28) :1794-1797
[9]   Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial [J].
Breithardt, Gunter ;
Baumgartner, Helmut ;
Berkowitz, Scott D. ;
Hellkamp, Anne S. ;
Piccini, Jonathan P. ;
Stevens, Susanna R. ;
Lokhnygina, Yuliya ;
Patel, Manesh R. ;
Halperin, Jonathan L. ;
Singer, Daniel E. ;
Hankey, Graeme J. ;
Hacke, Werner ;
Becker, Richard C. ;
Nessel, Christopher C. ;
Mahaffey, Kenneth W. ;
Fox, Keith A. A. ;
Califf, Robert M. .
EUROPEAN HEART JOURNAL, 2014, 35 (47) :3377-3385
[10]   Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis [J].
Caldeira, Daniel ;
David, Claudio ;
Costa, Joao ;
Ferreira, Joaquim J. ;
Pinto, Fausto J. .
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2018, 4 (02) :111-118